Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
ConditionStaphylococcus Aureus Bacteremia
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorIntermountain Health Care, Inc.
About this trial
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Eligibility criteria
Qualifiers
Age ≥18 years
Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
on or during the index admission to an IH hospital, or
in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
Disqualifiers
Patient requests that patient health data not be included in the analysis
Trial design
Treatments tested in this trial
- Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
- Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Treatment groups
2,096 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov